P53 deletion and NrasG12D cooperate for AML

Vainchenker, William; Plo, Isabelle

doi:10.1182/blood-2016-11-750547

Blood

2017

DOI: 10.1182/blood-2016-11-750547

|View full text |Cite

P53 deletion and NrasG12D cooperate for AML

William Vainchenker

Isabelle Plo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

Ahmadi,

Rahimian,

Rahimi

et al. 2024

Biomark Res

View full text Add to dashboard Cite

The p53 protein, encoded by the TP53 gene, serves as a critical tumor suppressor, playing a vital role in maintaining genomic stability and regulating cellular responses to stress. Dysregulation of p53 is frequently observed in hematological malignancies, significantly impacting disease progression and patient outcomes. This review aims to examine the regulatory mechanisms of p53, the implications of TP53 mutations in various hematological cancers, and emerging therapeutic strategies targeting p53. We conducted a comprehensive literature review to synthesize recent findings related to p53's multifaceted role in hematologic cancers, focusing on its regulatory pathways and therapeutic potential. TP53 mutations in hematological malignancies often lead to treatment resistance and poor prognosis. Current therapeutic strategies, including p53 reactivation and gene therapy, show promise in improving treatment outcomes. Understanding the intricacies of p53 regulation and the consequences of its mutations is essential for developing effective diagnostic and therapeutic strategies in hematological malignancies, ultimately enhancing patient care and survival.

show abstract

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

Ahmadi,

Rahimian,

Rahimi

et al. 2024

Biomark Res

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P53 deletion and NrasG12D cooperate for AML

Cited by 1 publication

References 9 publications

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

Contact Info

Product

Resources

About